gms | German Medical Science

59. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
3. Joint Meeting mit der Italienischen Gesellschaft für Neurochirurgie (SINch)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

01. - 04.06.2008, Würzburg

Human adult mesenchymal stem cells are recruited by malignant gliomas by secretion of SDF-1

Human adulte mesenchymale Stammzellen werden von malignen Gliomen durch SDF-1 Sekretion rekrutiert

Meeting Abstract

  • corresponding author C. Schichor - Neurochirurgische Klinik, Ludwig-Maximilians-Universität München
  • H. Theiss - Innere Medizin, Ludwig-Maximilians-Universität München
  • I. Krotofil - Neurochirurgische Klinik, Ludwig-Maximilians-Universität München
  • J.-C. Tonn - Neurochirurgische Klinik, Ludwig-Maximilians-Universität München
  • R. Goldbrunner - Neurochirurgische Klinik, Ludwig-Maximilians-Universität München

Deutsche Gesellschaft für Neurochirurgie. Società Italiana di Neurochirurgia. 59. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 3. Joint Meeting mit der Italienischen Gesellschaft für Neurochirurgie (SINch). Würzburg, 01.-04.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocDI.04.03

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 30. Mai 2008

© 2008 Schichor et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Objective: Aim of our study was to show whether human adult mesenchymal stem cells (hMSC) can be isolated from malignant glioma specimen, obtained from neurosurgical operations and to identify the role of stromal derived factor (SDF-1) as a contributing factor of their recruitment.

Methods: Glioma specimen of different grades (n=12) were included in our study. hMSCs were isolated by the use of a ficoll gradient. Isolated cells were intensively characterized by FACS-analysis as well as differentiation assays into mesenchymal lineages (fat, bone). SDF-1 was analyzed by ELISA in blood samples from glioma patients before and after administration of corticosteroids as an antiedematous therapy. SDF-1 was evaluated in the glioma tissue by qPCR. SDF-1 receptor (CXCR-4) expression of hMSC was analyzed.

Results: Only in high grade gliomas, by the use of intense FACS analysis, we found the cells isolated by our protocol to express typical surface markers of hMSCs and CXCR4, the receptor of SDF-1. Differentiation assays showed that the cells, although derived from malignant glioma tissue, exhibit differentiation potential into mesenchymal cell lines, producing fat or bone. Directed invasion of hMSC in vitro was increased in presence of a SDF-1 gradient. Malignant glioma tissue showed to overexpress SDF-1, compared to normal brain tissue, obtained from patients with epilepsy surgery. Serum-SDF-1 levels were elevated in patients with gliomas compared to healthy volunteers.

Conclusions: Malignant glioma tissue contains a progenitor cell type, resembling mesenchymal stem cell (hMSC) characteristics. This indicates active recruitment of these cells from the circulation by gliomas. As a possible mechanism for recruitment of hMSCs from bone marrow we identified the SDF-1 / CXCR4 system.